CCCC Q1 2021 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+8.9% YoY

Gross Profit

-$13M-176.4% margin

Operating Income

-$41M-552.6% margin

Net Income

-$21M-282.4% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-10.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$374M

Total Liabilities

$110M

Stockholders' Equity

$264M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	+8.9%
Gross Profit	-$13M	-$9M	-38.0%
Operating Income	-$41M	-$12M	-232.6%
Net Income	-$21M	-$12M	-76.0%